Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study ID
NCT06280508
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adebrelimab, Apatinib, Gemcitabine, cisplatin — DRUG
    Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery

Study Details

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

Key Dates

Start date
Mar 1, 2024
Status verified
Apr 2024
Primary completion
Mar 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment arm

Primary Outcome Measure

1-year EFS rate [ Time Frame: Up to approximately 3 years ]

Central Contacts